Replies to post #239515 on Biotech Values

[DewDiligence]

FWBI—>ENTO (Entero Therapeutics) effective 5/17/24:

https://www.globenewswire.com/news-release/2024/05/16/2883267/0/en/First-Wave-BioPharma-Changes-Name-to-Entero-Therapeutics.html

The name change stems from a reverse-merger that closed in Mar 2024, whereby FWBI merged with (then private) ImmunogenX, whose lead program is for celiac disease (https://finance.yahoo.com/news/first-wave-biopharma-announces-completion-100000036.html ).

FWBI was itself the product of a 2021 reverse-merger (#msg-165885811).